Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
8.91
-0.17 (-1.87%)
Dec 20, 2024, 4:00 PM EST - Market closed
Avalo Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Avalo Therapeutics stock have an average target of 33, with a low estimate of 24 and a high estimate of 40. The average target predicts an increase of 270.37% from the current stock price of 8.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AVTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +348.93% | Dec 19, 2024 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +169.36% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 24, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $35 | Hold → Buy | Upgrades | $35 | +292.82% | Apr 16, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 27, 2023 |
Financial Forecast
Revenue This Year
228.99K
from 1.92M
Decreased by -88.10%
Revenue Next Year
n/a
from 228.99K
EPS This Year
-37.22
from -113.58
EPS Next Year
-4.79
from -37.22
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 261,450 | n/a | n/a | ||
| Avg | 228,990 | n/a | n/a | ||
| Low | 196,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -86.4% | - | - | ||
| Avg | -88.1% | - | - | ||
| Low | -89.8% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -38.31 | -4.75 | -1.60 |
| Avg | -37.22 | -4.79 | -3.06 |
| Low | -35.76 | -4.78 | -4.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.